Alzheimer's disease and melatonin

Etsuro Matsubara, Mikio Shoji, Tetsuro Murakami, Takeshi Kawarabayashi, Koji Abe

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalInternational Congress Series
Issue numberC
Publication statusPublished - Jun 1 2003
Externally publishedYes


  • Alzheimer's disease
  • Amyloid β
  • Anti-amyloidogenic properties of melatonin
  • Antioxidant properties of melatonin
  • Melatonin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Alzheimer's disease and melatonin'. Together they form a unique fingerprint.

Cite this